( October 14, 2025, 09:28 GMT | Official Statement) -- MLex Summary: BioNTech has won German competition clearance for its acquisition of CureVac, the national competition authority said Tuesday, finding no significant overlaps in the companies' drug research pipelines. There are also no concerns with regard to mRNA technology, the office said, citing extensive research activities of large and globally active rivals in this area. The deal, to be completed through a share exchange, isn't expected to restrict innovation-based competition, Bundeskartellamt head Andreas Mundt said.Statement follows. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.